Inmode (INMD) Aktsia Kursus
Inmode Kursus
Viimase 9 aasta jooksul kasvas Inmode käive 36,1 % aastas ja jõudis 370,50 M USD-ni. Kasum aktsia kohta kasvas 83,2 % aastas viimase 9 aasta jooksul. Inmode netomarginaal 25,3 % on langenud võrreldes 46,1 %-ga mõni aasta tagasi. Inmode 12 kuu konsensuse hinnasiht on 19,00 USD, umbes üle kurssi 34,2 %. 12 analüütikust 6 soovitab osta — üldine konsensus on Osta.
Inmode aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Inmode ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Inmode aktsia kohta
The business model of Inmode Ltd revolves around providing innovative medical aesthetics solutions. Inmode Ltd develops and markets advanced, minimally-invasive technologies used in aesthetic and surgical procedures. Their cutting-edge platforms, such as BodyTite, FaceTite, and Morpheus8, offer solutions for skin tightening, body contouring, facial rejuvenation, and cellulite reduction. Inmode Ltd's business model centers on combining radiofrequency technology with other modalities to deliver safe, efficient, and customizable treatments for both medical professionals and patients. By continuously developing and enhancing their product portfolio, they aim to meet the growing demands of the global aesthetic market and cater to the evolving needs of healthcare practitioners.
Inmode Ltd is primarily active in the aesthetic medical device industry.
The main competitors of Inmode Ltd in the market include companies such as Cutera Inc., Cynosure Inc., Alma Lasers Ltd., and Lumenis Ltd. These companies offer similar products and services in the medical aesthetics industry, which Inmode operates in. With its innovative technologies and strong market presence, Inmode competes with these industry players to gain a larger market share and maintain its position as a leading provider of aesthetic solutions.
Inmode Ltd is a leading global provider of innovative energy-based medical aesthetic solutions. Established in 2008, the company has rapidly grown to become a trusted name in the industry. Inmode's cutting-edge technology focuses on radiofrequency-based devices, enabling physicians to deliver effective aesthetic treatments with precision and optimal patient satisfaction. Inmode Ltd is headquartered in Israel but operates worldwide, serving thousands of medical professionals and patients alike. With a commitment to continuously expanding its portfolio and investing in research and development, Inmode Ltd remains at the forefront of the medical aesthetics field, dedicated to enhancing the lives of individuals through advanced and safe technology.
Inmode Ltd, a leading provider of medical aesthetic systems, has achieved several significant milestones. The company has successfully pioneered advanced technology in minimally invasive and non-invasive procedures for aesthetic treatments. Inmode Ltd has gained worldwide recognition for its innovative platform, which includes advanced radiofrequency, laser, and pulsed light technologies. With a strong focus on research and development, they have introduced cutting-edge solutions that address a wide range of aesthetic concerns effectively and safely. Inmode Ltd continues to revolutionize the field of medical aesthetics, solidifying its position as a market leader and providing patients with exceptional treatment options.
Inmode Ltd is primarily present in various countries and regions worldwide. The company's presence extends to the United States, where it has a significant market presence. In addition, Inmode Ltd has established a strong presence in Europe, including key markets such as Germany, France, Italy, and the United Kingdom. The company also operates in the Asia-Pacific region, with a focus on countries like China and Japan. With its global reach, Inmode Ltd continues to expand its presence and deliver innovative solutions in the field of aesthetic medical technology.
Inmode Ltd represents a strong set of core values and a corporate philosophy that distinguishes the company. With a focus on innovation and cutting-edge technology, Inmode aims to provide transformative solutions in the aesthetic and medical markets. The company prides itself on quality, reliability, and versatility, ensuring that customers can trust their products and services. Inmode's commitment to research and development enables them to deliver advanced solutions, empowering healthcare professionals to enhance patient care and achieve optimal results. By prioritizing customer satisfaction and continuous improvement, Inmode Ltd strives to remain a leader in the industry.
Analüütikud määravad Inmode aktsiale keskmiseks hinnasihi 19,00 USD (mediaan: 19,00 USD), mis on +34,2 % viimase hinna suhtes. Konsensus põhineb 12 analüütiku hinnangul.
12 analüütikut hindavad praegu Inmode aktsiat: 6 soovitab osta, 6 hoida ja 0 müüa. 2026. aastaks ootavad analüütikud, et Inmode teenib tulu 370,32 M USD ja kasumit aktsia kohta 1,28 USD.
Praeguse kursiga kaubeldakse Inmode aktsiaga 12,61 EUR (14,16 USD) juures.
Inmode aktsia (INMD) on noteeritud 4 börsil, sh: NASDAQ (INMD), Frankfurt (154.F), München (154.MU), Düsseldorf (154.DU).
Inmode Ltd is a leading company in the medical technology industry, specializing in the development and commercialization of innovative aesthetic solutions. The company offers a wide range of products and services aimed at providing patients with fast, safe, and effective treatment for aesthetic problems. Inmode specializes in four main areas: body contouring and fat reduction, skin tightening, wrinkle reduction and skin rejuvenation, and common skin problems. To address these areas, the company has developed various advanced technologies and devices available to doctors and clinics. These include: - BodyTite: A revolutionary technology that uses radiofrequency energy to melt tissue, leading to effective body contouring with minimal invasiveness. - FaceTite: A technology based on the same principles as BodyTite but specifically developed for the face and neck to tighten loose skin and reduce wrinkles. - Morpheus8: A combination of micro-needles and radiofrequency energy that stimulates collagen production and tightens the skin, reducing wrinkles and unevenness. - Votiva: A device specifically designed for women that tightens the vagina and improves sexual health. These areas and products aim to cover the entire spectrum of aesthetic needs in order to build a successful and growing customer base. Inmode also has a unique business model that goes beyond traditional sales efforts. The company has developed a strong online presence that provides potential customers with everything they need to know about the company's products and services. Inmode has also built close relationships with medical professionals around the world to ensure that their products and technologies meet the highest medical standards. In addition to providing advanced medical devices to doctors and clinics, Inmode has also developed comprehensive training and support programs to ensure that doctors and clinics are trained in the use of their technologies and can achieve the best possible results for their patients. This business model has contributed to the company's growth and success in recent years, becoming a key factor in the aesthetic medicine industry. Overall, Inmode's business model demonstrates how innovative technologies and high-quality products and services, combined with online marketing and customer relationships, can lead to a successful company.
oodatav Inmode käive on 370,32 M USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav Inmode kasum on 82,11 M USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Inmode jaoks on praegu 11,05. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Inmode aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Inmode jaoks on praegu 2,45. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Inmode aktsia jaoks.
Eulpooli kvaliteedinäitaja Inmode jaoks on 3/10.
Inmode ISIN on IL0011595993. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Inmode WKN on A2PP3A. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Inmode ticker on INMD. Ticker-sümbol kasutatakse Inmode aktsiate kauplemiseks börsil.
Inmode aktsia
Inmode Börsiticker
Inmode FIGI
Kõik teised näitajad ja analüüsid Inmode kohta sügavamalt
Meie Inmode-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Inmode. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: